Ani Pharmaceuticals, Inc. · NASDAQ:ANIP

Ani Pharmaceuticals — Investor Presentation (June 2024)

20 slides from Ani Pharmaceuticals's investor presentation, Jun 5, 2024

Slide 2: Disclaimer
© 2024 ANI Pharmaceuticals, Inc. 2 Disclaimer To the extent any statements made in this presentation deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not lim
Slide 3: ANI Pharmaceuticals: Rare Disease and Generics drive robust profitable growth
© 2024 ANI Pharmaceuticals, Inc. 3 ANI Pharmaceuticals: Rare Disease and Generics drive robust profitable growth; Established Brands adds strong cash flow Key Growth Drivers Rare Disease business with lead asset Purified Cortrophin® Gel and expansion through M&A and in-licensing Generics with enhanc
Slide 4: ANI has delivered high revenue growth consistently since 2021
© 2024 ANI Pharmaceuticals, Inc. 4 ANI has delivered high revenue growth consistently since 2021; Rare Disease expected to be largest driver of growth going forward 2022 2023 2024E $42 $112 $170-180 Rare Disease Revenues ($ millions)(1),(3)Total Company Revenues ($ millions)(1),(3) 105% CAGR(2) 2021
Slide 5: Topline growth and Rare Disease operating leverage expected to drive continued strong EBITDA growth
© 2024 ANI Pharmaceuticals, Inc. 5 Topline growth and Rare Disease operating leverage expected to drive continued strong EBITDA growth Adjusted Non-GAAP Gross Profit (1) ($ millions) Adjusted Non-GAAP EBITDA(1) ($ millions) 2022 2023 2024E $56 $134 $135-145(1) +58%(2) 2022 2023 2024E $183 $310 $329-
Slide 6: Momentum continues in 2024 with ANI delivering record results in Q1
© 2024 ANI Pharmaceuticals, Inc. 6 Q1 Adj. non-GAAP EBITDA(1) $38M 14% YoY Momentum continues in 2024 with ANI delivering record results in Q1 Q1 Revenues $137M 29% YoY Q1 Diluted non-GAAP EPS(1) $1.21 3% YoY Q1 Rare Disease Revenues $37M 126% YoY Q1 Adj. non-GAAP Net Income $23M Q1 Generic, Establi
Slide 7: 2024 Guidance
© 2024 ANI Pharmaceuticals, Inc. 7 2024 Guidance 1. Adjusted Non-GAAP Gross Margin, Adjusted Non-GAAP EBITDA, and Adjusted Non-GAAP Diluted EPS are Non-GAAP financial measures. 2. 2024 guidance initially provided on February 29, 2024, and reiterated on May 10, 2024. Metric ($ millions except per sha
Slide 8: ANI Rare Disease: the story behind long-term sustainable lead asset Purified Cortrophin Gel
© 2024 ANI Pharmaceuticals, Inc. 8 ANI Rare Disease: the story behind long-term sustainable lead asset Purified Cortrophin® Gel Cortrophin Gel is purified corticotropin (ACTH), a treatment option for patients struggling with certain chronic autoimmune disorders Limited competition (only one other AC
Slide 9: Rare Disease: ANI's primary growth engine accelerating with lead asset Purified Cortrophin Gel
© 2024 ANI Pharmaceuticals, Inc. 9 • Launched 1-mL vial size of Cortrophin Gel during Q4 2023, the only approved ACTH therapy indicated for the treatment of acute gouty arthritis flares • Given strong traction in pulmonology, added a second geographical region to pulmonology sales force in Q1 2024 •
Slide 10: ACTH market is expected to return to growth in 2024
© 2024 ANI Pharmaceuticals, Inc. 10 ACTH market is expected to return to growth in 2024 and we believe Cortrophin Gel remains on a strong multi-year growth trajectory 2019 2020 2021 2022 2023 2024E(1) $953 $768 $594 $558 $537 $580-$590 Acthar Gel Purified Cortrophin® Gel ACTH Market Sales ($ million
Slide 11: Focused efforts ongoing to increase scope and scale of Rare Disease business through M&A and in-licensing
© 2024 ANI Pharmaceuticals, Inc. 11 Focused efforts ongoing to increase scope and scale of Rare Disease business through M&A and in-licensing Assets’ patent protection profile Assets’ peak year revenue forecast Priority 1: Rare disease opportunities in priority therapeutic areas of nephrology, neuro
Slide 12: Strong balance sheet to support Rare Disease business development
© 2024 ANI Pharmaceuticals, Inc. 12 Strong balance sheet to support Rare Disease business development 2022 2023 Q1’2024(2) Cash & Cash Equivalents $48M $221M $229M Net Debt/EBITDA 4.4x 0.5x 0.5x Gross Debt $297M $294M $293M Net Debt $249M $73M $64M Adjusted Non-GAAP EBITDA (1) $56M $134M $138M Note:
Slide 13: Superior R&D capabilities and operational excellence driving growth in Generics
© 2024 ANI Pharmaceuticals, Inc. 13 Superior R&D capabilities and operational excellence driving growth in Generics Robust pipeline and new product launch execution • Launched six new products during Q1 2024, including a Competitive Generic Therapy (CGT) product with 180-day exclusivity • Number two
Slide 14: U.S.-based manufacturing footprint; strong GMP track record
© 2024 ANI Pharmaceuticals, Inc. 14 U.S.-based manufacturing footprint; strong GMP track record, including successful FDA audits at all three sites • Manufacturing, packaging, warehouse • Schedule CII vault & CIII cage space • Lab space - R&D/analytical testing • Solutions, suspensions, topicals, ta
Slide 15: Executive leadership team with proven track records and broad industry expertise
© 2024 ANI Pharmaceuticals, Inc. 15 Executive leadership team with proven track records and broad industry expertise ‒ 20+ years leadership experience in pharmaceuticals and healthcare ‒ Proven track record of developing and executing multi-year strategic growth plans Nikhil Lalwani President & Chie
Slide 16: Investment summary
© 2024 ANI Pharmaceuticals, Inc. 16 Investment summary Strong and growing Rare Disease business, largest driver of growth • Largest expected driver of future growth • Lead asset Cortrophin Gel forecasted at $170- $180M revenues in 2024(1) (+52% - 61%) with significant multi-year future growth opport
Slide 18: Adjusted non-GAAP EBITDA calculation – 1Q 2024 and 2023
© 2024 ANI Pharmaceuticals, Inc. 18 Adjusted non-GAAP EBITDA calculation – 1Q 2024 and 2023 (1) Impact of Canada operations includes CDMO revenues, cost of sales relating to CDMO revenues, all selling, general, and administrative expenses, and all research and development expenses recorded in Canada
Slide 19: Adjusted non-GAAP EPS calculation – 1Q 2024 and 2023
© 2024 ANI Pharmaceuticals, Inc. 19 Adjusted non-GAAP EPS calculation – 1Q 2024 and 2023 (1) Impact of Canada operations includes CDMO revenues, cost of sales relating to CDMO revenues, all selling, general, and administrative expenses, and all research and development expenses recorded in Canada in

ANI Pharmaceuticals — Investor Presentation (June 2024) on 6ix

Ani Pharmaceuticals — Investor Presentation (June 2024)

Slide 1: June 2024

Slide 2: Disclaimer

Slide 3: ANI Pharmaceuticals: Rare Disease and Generics drive robust profitable growth

Slide 4: ANI has delivered high revenue growth consistently since 2021

Slide 5: Topline growth and Rare Disease operating leverage expected to drive continued strong EBITDA growth

Slide 6: Momentum continues in 2024 with ANI delivering record results in Q1

Slide 7: 2024 Guidance

Slide 8: ANI Rare Disease: the story behind long-term sustainable lead asset Purified Cortrophin Gel

Slide 9: Rare Disease: ANI's primary growth engine accelerating with lead asset Purified Cortrophin Gel

Slide 10: ACTH market is expected to return to growth in 2024

Slide 11: Focused efforts ongoing to increase scope and scale of Rare Disease business through M&A and in-licensing

Slide 12: Strong balance sheet to support Rare Disease business development

Slide 13: Superior R&D capabilities and operational excellence driving growth in Generics

Slide 14: U.S.-based manufacturing footprint; strong GMP track record

Slide 15: Executive leadership team with proven track records and broad industry expertise

Slide 16: Investment summary

Slide 17: Appendix A

Slide 18: Adjusted non-GAAP EBITDA calculation – 1Q 2024 and 2023

Slide 19: Adjusted non-GAAP EPS calculation – 1Q 2024 and 2023

Slide 20: June 2024